Stoke Therapeutics, Inc. — Form 4
Filed July 17, 2026 · analyzed by the Insider Agent
4
— Neutral
significance 22/100
What the filing says
Chief Scientific Officer McCauley Thomas (STOK) received 225K shares (equity award). Routine compensation — limited price signal.
Why this rating
Routine compensation — limited price signal.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.